普通外文研报
Flywire 2Q Recap: Another Execution-Driven Beat and FY26 Raise, but Peak-Season Edu Visibility Keeps Us Neutral
研报英文原文证据摘录
J P M O R G A N
North America Equity Research
05 August 2026
Flywire
2Q Recap: Another Execution-Driven Beat and FY26
Raise, but Peak-Season Edu Visibility Keeps Us
Neutral
FLYW, FLYW US
Price (04 Aug 26):$17.26
▲Price Target (Dec-27):$20.00
Prior (Dec-26):$16.00
FLYW delivered another execution-driven beat in 2Q despite a tough macro and
regulatory climate, beating our estimates across key metrics with FY26 outlook
raised beyond the beat. Revenue grew +27% y/y FXN, ~5% above our/Street
expectations, with adj. EBITDA margin expansion ~80bps above at +160 bps y/y.
FY26 FXN organic revenue growth was raised to 19.5%-25.5% (from 16.5%22.5%) and EBITDA margin expansion to +200 to +400 bps (from +175 to +375
prior) despite higher-than-anticipated gross margin pressure as payment
processing ramps faster across Healthcare and B2B. We are taking up FY26
numbers accordingly, but maintain FY27 notional estimates given (1) peak-season
uncertainty in the UK and Australia as visa trends and policy remain fluid, and (2)
a possible pull-forward of payment processing tailwinds into 2H, and it is too early
to call for replenishment next year. Net, we are incrementally more constructive on
management execution and the competitiveness of FLYW’s platform, but we
remain Neutral given a more balanced risk-reward until we have cleaner reads on
peak-season demand and the durability of growth into FY27. We establish a
December 2027 price target of $20, which applies a 3.5x multiple on our CY28E
gross profit (our prior Dec-26 PT was $16).
2Q summary. FLYW reported revenue of $164M (vs JPMe/Street $156.5M),
representing 27% y/y FXN growth, which exceeded the top end of guidance
range by 3ppts (vs 7ppt beat last Q). Adj gross profit of $93M came in above
JPMe/Street $88.5/$89.8M on adj gross margin of 56.6% vs JPMe/Street
56.5%/57.4%, down ~450bps y/y, of which mgmt attributes ~300bps from
executing large payment processing ramps from healthcare and B2B and the
balance to vertical mix shifts. Adj EBITDA of $24M exceeded JPMe/Street
$21.7M on strong cost discipline and operating leverage, reflecting adj
EBITDA margin of 14.6% (+160 bps y/y) vs JPMe/Street 13.9%/13.9%
…
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器